The JV will be led by Dr Axel Bouchon, head of the BLSC, on an interim basis as CEO, while Dr Rodger Novak, CEO and co-founder of CRISPR Therapeutics, will serve as the interim chairman of the ...

Dr Emmanuelle Charpentier is the founder of CRISPR Therapeutics, and one of the scientists credited with its discovery. However Charpentier is competing with rivals and former colleagues who have ...

CRISPR Therapeutics AG is a gene editing company ... and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson ...

Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy ...

The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.